FDA Aims To Clear Hurdles For Severe Bleeding Products With Workshop, Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Community consent and other controversial practices involved with enrolling trauma patients in clinical trials will be addressed.
You may also be interested in...
Astellas Pays, And Pays Big, To Extend VelocImmune License With Regeneron
The Japanese pharma is paying $165 million upfront for continued access to the fully human monoclonal antibody discovery platform through 2018.
Astellas Pays, And Pays Big, To Extend VelocImmune License With Regeneron
The Japanese pharma is paying $165 million upfront for continued access to the fully human monoclonal antibody discovery platform through 2018.
Financings Of The Fortnight: Tough To Diagnose Meaning Of Genmark's IPO
The small diagnostic firm's reverse merger followed by a smallish IPO might be a harbinger of financings to come. Or not.